AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28121231 — intervention group
Group type: COMPARATOR
Intervention: Essen regimen
Number of subjects: 0
Study 28121231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 0
Study 28122201 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-02545920, single oral dose administration, dosage not specified
Number of subjects: 0
Study 28122522 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling (ratings 12-13 on Borg's perceived exertion scale) for 15 minutes
Number of subjects: 49
Study 28122522 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity cycling (ratings 15-17 on Borg's perceived exertion scale) for 15 minutes
Number of subjects: 49
Study 28122522 — intervention group
Group type: COMPARATOR
Intervention: Self-reported pain and fatigue during exercise
Number of subjects: 49
Study 28122648 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota Transfer Therapy (MTT) involving a 2-week antibiotic treatment, bowel cleanse, and extended fecal microbiota transplant (FMT) with a high initial dose followed by daily lower maintenance doses for 7-8 weeks.
Number of subjects: 0
Study 28122648 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota Transfer Therapy (MTT)
Number of subjects: 0
Study 28122782 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28123751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS) before airway clearance techniques (ACT)
Number of subjects: 13
Study 28123751 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (HTS) during airway clearance techniques (ACT)
Number of subjects: 13
Study 28123764 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline chemotherapy
Number of subjects: 165
Study 28123778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy
Number of subjects: 577
Study 28123778 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab combination therapy
Number of subjects: 577
Study 28123778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (both MONO and COMBO)
Number of subjects: 577
Study 28123890 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated and expanded natural killer (NKAE) cells plus anti-myeloma drugs
Number of subjects: 5
Study 28124820 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0
Study 28125096 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin (PG) labor induction
Number of subjects: 1275
Study 28125608 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia Miltiorrhiza Depside Salt for Infusion (SMDS)
Number of subjects: 30180
Study 28126019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-EMS physician treatment (intervention group)
Number of subjects: 3010
Study 28126019 — intervention group
Group type: COMPARATOR
Intervention: Conventional EMS physician treatment (control group)
Number of subjects: 3010
Study 28126272 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA)
Number of subjects: 135
Study 28126961 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-mediated lymphodepletion
Number of subjects: 0
Study 28127388 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) programme
Number of subjects: 84
Study 28127388 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 84
Study 28127388 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of IMR
Number of subjects: 84
Study 28127388 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR implementation
Number of subjects: 84
Study 28128731 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tobacco cessation training program
Number of subjects: 281
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling treatments
Number of subjects: 8
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 8
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 8
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Number of subjects: 8
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressors
Number of subjects: 8
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 8
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 8
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 8
Study 28128878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acidosis and rhabdomyolysis
Number of subjects: 8
Study 28129359 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients (CD and UC)
Number of subjects: 172
Study 28129359 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients (CD)
Number of subjects: 172
Study 28129359 — intervention group
Group type: EXPERIMENTAL
Intervention: CD patients
Number of subjects: 172
Study 28129359 — intervention group
Group type: COMPARATOR
Intervention: IBD patients
Number of subjects: 172
Study 28129526 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgens added to maintenance therapy
Number of subjects: 330
Study 28129526 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy without androgens
Number of subjects: 330
Study 28129783 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week Internet-based self-help therapy intervention
Number of subjects: 438
Study 28129783 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control for 32 weeks
Number of subjects: 438
Study 28129789 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic ablative radiotherapy (SABR) delivered using risk-adapted fractionation (54Gy/3 fractions, 55/5 or 60/8) before surgery.
Number of subjects: 10
Study 28129789 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery planned 10 weeks after SABR.
Number of subjects: 10
Study 28130080 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal concentric contractions in persons with MS
Number of subjects: 52
Study 28130080 — intervention group
Group type: COMPARATOR
Intervention: Maximal concentric contractions in healthy subjects
Number of subjects: 52
Study 28130083 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 422
Study 28130083 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and medical factors
Number of subjects: 422
Study 28130083 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 422
Study 28130083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 422
Study 28130083 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL)
Number of subjects: 422
Study 28130083 — intervention group
Group type: EXPERIMENTAL
Intervention: Client Satisfaction Questionnaire
Number of subjects: 422
Study 28130083 — intervention group
Group type: EXPERIMENTAL
Intervention: Craig Handicap Assessment and Reporting Technique Short Form
Number of subjects: 422
Study 28130212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg/d and dexamethasone 20 or 40 mg once per week
Number of subjects: 28
Study 28130212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 2 mg/d and dexamethasone 20 or 40 mg once per week
Number of subjects: 28
Study 28130212 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 28
Study 28130688 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI-123 model before ICU admission (age, baseline serum creatinine, diabetes, type of admission)
Number of subjects: 4480
Study 28130688 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI-23 model (includes height and weight)
Number of subjects: 4480
Study 28130688 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI-123 model after 24 hours
Number of subjects: 4480
Study 28130688 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI-23 model after 24 hours
Number of subjects: 4480
Study 28130688 — intervention group
Group type: COMPARATOR
Intervention: NGAL measured at ICU admission
Number of subjects: 4480
Study 28131167 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066 (carbidopa and levodopa extended-release capsules)
Number of subjects: 43
Study 28131394 — intervention group
Group type: EXPERIMENTAL
Intervention: VAR2CSA fused to HA TM-CT
Number of subjects: 0
Study 28131394 — intervention group
Group type: EXPERIMENTAL
Intervention: VAR2CSA HA TM-CT
Number of subjects: 0
Study 28131394 — intervention group
Group type: EXPERIMENTAL
Intervention: VAR2CSA MMTV TM-CT
Number of subjects: 0
Study 28131394 — intervention group
Group type: COMPARATOR
Intervention: Soluble VAR2CSA protein vaccine
Number of subjects: 0
Study 28131394 — intervention group
Group type: COMPARATOR
Intervention: Protein double-boost immunizations
Number of subjects: 0
Study 28131758 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback training
Number of subjects: 8
Study 28131785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.
Number of subjects: 270
Study 28131785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in patients with PD-L1 expression of 5% or greater.
Number of subjects: 270
Study 28131785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in patients with PD-L1 expression of 1% or greater.
Number of subjects: 270
Study 28131785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in patients with PD-L1 expression of less than 1%.
Number of subjects: 270
Study 28131785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment-related adverse events.
Number of subjects: 270
Study 28131785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab treatment-related deaths.
Number of subjects: 270
Study 28132013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal functional MRIs (fMRIs) used in predictive model creation and validation.
Number of subjects: 601
Study 28132013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal functional MRIs (fMRIs) used in predictive model validation.
Number of subjects: 601
Study 28132705 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile Justice Behavioral Health Services Cascade framework
Number of subjects: 0
Study 28132705 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse treatment
Number of subjects: 0
Study 28132705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions and policies to improve interagency coordination
Number of subjects: 0
Study 28132793 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 11234
Study 28132793 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score system based on 7 baseline clinical variables
Number of subjects: 11234
Study 28132793 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model validation
Number of subjects: 11234
Study 28132845 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor treatment (4 weeks)
Number of subjects: 16
Study 28132845 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor treatment (48 weeks)
Number of subjects: 16
Study 28134564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) insulin delivery system
Number of subjects: 124
Study 28134617 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (pharmacological challenge)
Number of subjects: 0
Study 28134742 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine challenge after initial anti-HBs testing
Number of subjects: 350
Study 28135273 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated JE vaccine SA14-14-2
Number of subjects: 16
Study 28135777 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg) + Daclatasvir (60 mg) once daily for 12 weeks
Number of subjects: 106
Study 28135777 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg) + Daclatasvir (60 mg) once daily for 24 weeks
Number of subjects: 106
Study 28135777 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg) + Daclatasvir (60 mg)
Number of subjects: 106
Study 28137255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention according to Norwegian dietary guidelines for 12 months and maintenance for 14 years
Number of subjects: 500
Study 28137255 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (control group)
Number of subjects: 500
Study 28137255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention
Number of subjects: 500
Study 28137269 — intervention group
Group type: EXPERIMENTAL
Intervention: Eadi-optimized PSV
Number of subjects: 11
Study 28137269 — intervention group
Group type: COMPARATOR
Intervention: Baseline PSV as set by the clinician
Number of subjects: 11
Study 28137269 — intervention group
Group type: EXPERIMENTAL
Intervention: Eadi-optimized PSV + PEEP adjustment
Number of subjects: 11
Study 28137269 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV
Number of subjects: 11
Study 28137489 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled severe-asthma
Number of subjects: 351799
Study 28137489 — intervention group
Group type: COMPARATOR
Intervention: Non-severe asthma
Number of subjects: 351799
Study 28137489 — intervention group
Group type: COMPARATOR
Intervention: Non-asthmatics
Number of subjects: 351799
Study 28137489 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled severe-asthmatics
Number of subjects: 351799
Study 28137593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 12 weeks (90/400 mg once daily)
Number of subjects: 53
Study 28137593 — intervention group
Group type: COMPARATOR
Intervention: Ledipasvir-sofosbuvir for 8 weeks (90/400 mg once daily)
Number of subjects: 53
Study 28137708 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Number of subjects: 89
Study 28138001 — intervention group
Group type: EXPERIMENTAL
Intervention: 10th percentile cerebral blood volume (CBV) at threshold of 0.47
Number of subjects: 83
Study 28138001 — intervention group
Group type: EXPERIMENTAL
Intervention: 90th percentile microvascular permeability (K2) at threshold of 0.28
Number of subjects: 83
Study 28138001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 10th percentile CBV and 90th percentile K2
Number of subjects: 83
Study 28138028 — intervention group
Group type: EXPERIMENTAL
Intervention: Chk1/2 inhibition with prexasertib combined with EGFR inhibitor cetuximab and radiotherapy
Number of subjects: 0
Study 28138062 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroSoft coils
Number of subjects: 599
Study 28138556 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 43
Study 28138560 — intervention group
Group type: EXPERIMENTAL
Intervention: BTK inhibitor ibrutinib
Number of subjects: 0
Study 28139016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular (IA) Autologous Protein Solution (APS) 50 μl from a human donor
Number of subjects: 30
Study 28139016 — intervention group
Group type: COMPARATOR
Intervention: Phosphate buffered saline (PBS) control
Number of subjects: 30
Study 28139235 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour Transtar stapler (the Rouen technique)
Number of subjects: 111
Study 28139235 — intervention group
Group type: EXPERIMENTAL
Intervention: End to end anastomosis circular transanal stapler
Number of subjects: 111
Study 28139235 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Gastrointestinal Quality of Life Index
Number of subjects: 111
Study 28139235 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation improvement
Number of subjects: 111
Study 28139235 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of pregnancy at 1 year after arrest of medical treatment
Number of subjects: 111
Study 28139432 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive dexamethasone
Number of subjects: 818
Study 28139432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteraemia
Number of subjects: 818
Study 28139432 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolisteriosis
Number of subjects: 818
Study 28139432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing cancer
Number of subjects: 818
Study 28139432 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-organ failure
Number of subjects: 818
Study 28139432 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggravation of any pre-existing organ dysfunction
Number of subjects: 818
Study 28139432 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytopenia
Number of subjects: 818
Study 28139432 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal-neonatal infections
Number of subjects: 818
Study 28140719 — intervention group
Group type: EXPERIMENTAL
Intervention: Delanzomib (CEP-18770) at maximum tolerated dose (MTD) of 2.1 mg/m², administered on days 1, 8, and 15 in 28-day cycles.
Number of subjects: 61
Study 28143434 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIM-DWI and 3D-ASL imaging techniques
Number of subjects: 0
Study 28143434 — intervention group
Group type: COMPARATOR
Intervention: Conventional MRI
Number of subjects: 0
Study 28143434 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analyses
Number of subjects: 0
Study 28143447 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once-daily for 5 months
Number of subjects: 602
Study 28143518 — intervention group
Group type: EXPERIMENTAL
Intervention: uPCR for Plasmodium infections
Number of subjects: 1000
Study 28143518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical malaria cases diagnosed by village malaria workers
Number of subjects: 1000
Study 28143518 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of P. vivax prevalence with malaria incidence
Number of subjects: 1000
Study 28143620 — intervention group
Group type: EXPERIMENTAL
Intervention: Current-smokers
Number of subjects: 99
Study 28143620 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 99
Study 28143620 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AWT Pi10
Number of subjects: 99
Study 28143620 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 99
Study 28143674 — intervention group
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Number of subjects: 100
Study 28143815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 6194
Study 28144789 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5363 combined with docetaxel and prednisolone chemotherapy (DP)
Number of subjects: 0
Study 28144789 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and prednisolone chemotherapy (DP)
Number of subjects: 0
Study 28144917 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 1808
Study 28146642 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0
Study 28146642 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard treatment)
Number of subjects: 0
Study 28148221 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal adjuvanted influenza vaccine (Fluad™, Novartis) with five follow-up visits (day 0, 1/3, 7, 21, 70)
Number of subjects: 5582
Study 28148221 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipation
Number of subjects: 5582
Study 28148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin assessment
Number of subjects: 204
Study 28148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) usage
Number of subjects: 204
Study 28148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor (TNF) blockers usage
Number of subjects: 204
Study 28148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of Crohn's disease (CD)
Number of subjects: 204
Study 28148281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin correlation with disease activity
Number of subjects: 204
Study 28148635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation (HDIT/HCT)
Number of subjects: 24
Study 28148680 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proteome analysis
Number of subjects: 0
Study 28149573 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-COPD overlap syndrome (ACOS)
Number of subjects: 2000
Study 28149573 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 2000
Study 28149573 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 2000
Study 28149573 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bronchitis
Number of subjects: 2000
Study 28149573 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema
Number of subjects: 2000
Study 28150230 — intervention group
Group type: EXPERIMENTAL
Intervention: MC4R rs489693 AA genotype
Number of subjects: 55
Study 28150230 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and temozolomide
Number of subjects: 55
Study 28150872 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan followed by HSCT
Number of subjects: 108
Study 28150872 — intervention group
Group type: EXPERIMENTAL
Intervention: TT variant of ANRIL
Number of subjects: 108
Study 28151941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (training and support in intensive multifactorial treatment)
Number of subjects: 4107
Study 28151941 — intervention group
Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 4107
Study 28151941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intensive treatment and routine care)
Number of subjects: 4107
Study 28152086 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTT120 (0.1 mg/kg, 0.3 mg/kg, 1 mg/kg)
Number of subjects: 21
Study 28152086 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTT120 (0.3 mg/kg, 1 mg/kg)
Number of subjects: 21
Study 28152086 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTT120
Number of subjects: 21
Study 28152315 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis
Number of subjects: 444
Study 28152975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation to recommended volume (#3: 60 ml, #4: 80 ml, #5: 90 ml)
Number of subjects: 60
Study 28152975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure (CP) of 60 cmH2O
Number of subjects: 60